| Rank |
Status |
Study |
| 1 |
Unknown †
|
The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
| Condition: |
Peritoneal Membrane Failure |
| Interventions: |
Drug: placebo; Drug: Aliskiren; Drug: Aliskiren plus Losartan; Drug: Enalapril plus Losartan |
| Outcome Measures: |
Changing in modified peritoneal equilibrium test; appearance rate of dialysate CA125; nutritional status; adverse events |
|
| 2 |
Unknown †
|
Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients
| Condition: |
Marfan Syndrome |
| Interventions: |
Drug: Losartan and nebivolol; Drug: Losartan; Drug: Nebivolol |
| Outcome Measures: |
BSA and age-adjusted aortic root diameter (sinuses of Valsalva); The pharmacokinetics of the two drugs by age and dosages; Comparative evaluation of the serum levels of total and active TGFb; Quantitative assessment of the expression of the mutated gene (FBN1, both 5' and 3'); Pharmacogenetic bases of drug responsiveness (Losartan: CYP2C9 gene) (Nebivolol: CYP2D6 gene); Aortic valve regurgitation severity; Left ventricular end-diastolic diameter; Left ventricular ejection fraction; Spirometric lung volumes and flows; QoL evaluation basing on SF-36 questionnaire; Arterial stiffness (carotids) |
|
| 3 |
Recruiting
|
Losartan for Sickle Cell Kidney Disease
| Condition: |
Sickle Cell Disease |
| Intervention: |
|
| Outcome Measures: |
Effects of Losartan; chronic angiotensin blockade |
|
| 4 |
Recruiting
|
Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
| Condition: |
Nonalcoholic Steatohepatitis |
| Intervention: |
Drug: Losartan |
| Outcome Measures: |
The primary outcome will be change in Kleiner fibrosis score, [Kleiner DE et al Hepatology 2005], based on histological fibrosis stage (as judged by two independent blinded histopathologists from liver biopsies), from pre-treatment to end-of-study; Change in radiological (fibroscan) and serological (ELF) markers of fibrosis; change in NAFLD activity score (NAS); comparison of "responder rate" - placebo versus intervention |
|
| 5 |
Recruiting
|
Study of Losartan in the Treatment of NAFLD in Children
| Condition: |
NAFLD |
| Intervention: |
Drug: Losartan |
| Outcome Measures: |
Change in ALT from baseline to week 8 and/or week 22; Changes in cholesterol and fatty acid levels; Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR), insulin and glucose; Changes in Plasminogen activator inhibitor-1 (PAI-1) |
|
| 6 |
Recruiting
|
Cozaar XQ Re-examination Study (MK-0954-349)
| Condition: |
Hypertension |
| Intervention: |
Drug: amlodipine/losartan |
| Outcome Measures: |
Number of participants with any adverse experience; Change of sitting systolic and diastolic blood pressure (SiSBP, SiDBP) after treatment and overall efficacy evaluation by investigator |
|
| 7 |
Not yet recruiting
|
Comparison of Losartan Associated With Indapamide Versus Indapamide for Treatment of Hypertension
| Condition: |
Hypertension |
| Interventions: |
Drug: Indapamide / Losartan; Drug: Indapamide |
| Outcome Measures: |
Changes in systemic blood pressure measurements during 12 weeks; Percentage (%) of patients with blood pressure < 140 / 90 mmHg during 12 weeks, will be obtained comparing the differences between initial blood pressure (initial visit) and final (final visit).; Percentage (%) of patients excluded from the study because of treatment failure; Time to appropriate control of systolic blood pressure and diastolic blood pressure (BP <140/90 mmHg.; Incidence of any adverse events;; Incidence of hypotension; Incidence of serious adverse events and unexpected drug reactions |
|
| 8 |
Recruiting
|
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
| Conditions: |
HIV Infection; HIV Infections |
| Interventions: |
Drug: Losartan; Drug: Placebo |
| Outcome Measures: |
The primary endpoint is to determine the impact of losartan treatment on lymphoid tissue (LT) fibrosis.; We will assess the impact of losartan on immune reconstitution and function.; We will determine the impact of losartan on immune activation in HIV infected, treated individuals.; We will assess the potential for losartan to reduce the size of the viral reservoir.; We will assess for any potential drug-drug interactions between losartan and antiretrovirals (ARVs). |
|
| 9 |
Recruiting
|
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
| Condition: |
Pancreatic Cancer |
| Interventions: |
Drug: FOLFIRINOX; Drug: Losartan; Radiation: Proton Beam Radiation |
| Outcome Measures: |
Feasibility of combining FOLFIRINOX-Losartan; Progression-Free Survival; Overall Survival for FOLFIRINOX + Proton Beam Radiation; Overall Survival for FOLFIRINOX Without Proton Radiation; Determine Toxicity FOLFIRINOX-Losartan; Determine Toxicity of FOLFIRINOX-Losartan and Proton Beam Radiation; Rate of Downstaging; Determine correlation of Somatic Gene Mutations and Outcome; Determine Correlation Between Circulating Biomarkers and Outcome |
|
| 10 |
Recruiting
|
Comparision of Blood Pressure Variability Between Amlodipine and Losartan
| Condition: |
Hypertension |
| Interventions: |
Drug: Amlodipine; Drug: Losartan |
| Outcome Measures: |
SD of visit-to-visit systolic blood pressure variability; Central systolic blood pressure; Augmentation index of central blood pressure; Standard deviation of within-visit systolic blood pressure variability; Coefficient of variation of visit-to-visit systolic blood pressure variability; Variation independent of the mean of visit-to-visit systolic blood pressure variability; 24-h ambulatory blood pressure monitoring; Home systolic blood pressure |
|
| 11 |
Recruiting
|
Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment
| Conditions: |
Hypertension; Sleep Apnea |
| Interventions: |
Drug: Losartan; Other: CPAP |
| Outcome Measures: |
24 h blood pressure (mean blood pressure; mmHg); Markers of sympathetic activity, RAAS-activity, cardiovascular biomarkers |
|
| 12 |
Recruiting
|
The Effect of Losartan in Bicuspid Aortic Valve Patients
| Conditions: |
Bicuspid Aortic Valve; Thoracic Aortic Aneurysm |
| Intervention: |
Drug: Cozaar |
| Outcome Measure: |
Inflammatory markers level |
|
| 13 |
Recruiting
|
Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency
| Condition: |
Renal Insufficiency, Chronic |
| Interventions: |
Drug: Benazepril; Drug: Losartan; Drug: Benazepril+Losartan |
| Outcome Measures: |
The proportion of patients with increase in serum potassium ≥6.0 mmol/L.; The proportion of patients with serum creatinine increase >30%; The proportion of patients with drug-related cough; The proportion of patients with hopotension (systolic blood pressure <110 mmHg despite withdrawal of all additional antihypertensive medication); The proportion of patients with non-fatal cardiovascular events |
|
| 14 |
Unknown †
|
A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
| Condition: |
Marfan Syndrome |
| Interventions: |
Drug: Losartan and Atenolol or Propranolol; Drug: Atenolol or Propranolol |
| Outcome Measure: |
Echocardiograms |
|
| 15 |
Recruiting
|
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
| Conditions: |
Glomerulonephritis; Proteinuria |
| Interventions: |
Drug: Shenyankangfu tablets; Drug: Losartan potassium 50mg; Drug: Shenyankangfu tablets and Losartan potassium 50mg; Drug: Shenyankangfu tablets and Losartan potassium 100mg; Drug: Losartan potassium 100mg |
| Outcome Measures: |
changes of 24 hours proteinuria after the treatment; changes of serum creatinine after treatment; changes of eGFR after the treatment; changes of Traditional Chinese Medicine syndrome scores after the treatment |
|
| 16 |
Recruiting
|
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
| Conditions: |
Eosinophilic Esophagitis; Connective Tissue Disorders |
| Intervention: |
Drug: Losartan Potassium |
| Outcome Measures: |
Number of participants with reduction of esophageal eosinophils; Number of participants with reduction in levels of the transforming growth factor beta protein.; Number of participants that experience normalization of the EoE transcriptome; Number of participants that have an improved score utilizing the Patient Reported Outcome questionnaires to assess for clinical symptom response.; Number of participants that have an improved score on the histology scoring system.; To determine the safety of Losartan |
|
| 17 |
Recruiting
|
Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
| Condition: |
HIV-1 |
| Interventions: |
Drug: EFV/FTC/TDF + Losartan; Drug: EFV/FTC/TDF; Drug: FTC/TDF + MK-0518; Drug: FTC/TDF+MK-0518+Losartan |
| Outcome Measures: |
Proportion of patients with 50% reduction of fibrosis in lymphatic tissue.; Proportion of patients with changes in the levels of IL-6, D-dimer and CRP in different groups.; Proportion of patients with increased CD4 in peripheral blood and in lymphatic tissue.; Proportion of patients with undetectable plasma viral load and decreased in lymphatic tissue in different groups; Proportion of patients with changes in the CD4/CD8 ratio in peripheral blood in different groups.; Proportion of patients with reduced intima-media complex in carotid ultrasound in different groups.; Proportion of patients with changes in levels of metalloproteinases and their inhibitors, beta2-microglobulin and CSF cells and proteins.; Proportion of patients with improvement in neuropsychological test CDS; Incidence and types of adverse events and laboratory abnormalities in the different groups. |
|
| 18 |
Recruiting
|
Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
| Condition: |
Marfan Syndrome |
| Interventions: |
Drug: Losartan; Drug: Placebo |
| Outcome Measures: |
The decrease of rate of aortic root growth measured by echocardiography at level of sinuses of Valsalva. The measure will be expressed in mm of growth per year and as Z-score.; Comparative arterial stiffness; Evaluation of progression of aortic regurgitation; Aortic dissection incidence; Aortic root surgery; Progression of mitral regurgitation; Left ventricular size and function; Skeletal and somatic traits; Quality of life; Genetic polymorphisms affecting clinical symptoms and response to treatment; Death; Aortic stiffness as assessed by MRI |
|
| 19 |
Unknown †
|
PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
| Condition: |
Hypertension |
| Intervention: |
Drug: losartan |
| Outcome Measure: |
|
|
| 20 |
Recruiting
|
A Study of Muscle Strength Maintenance in Older Adults
| Condition: |
Sarcopenia |
| Interventions: |
Drug: Losartan; Drug: Placebo |
| Outcome Measures: |
Change from baseline in isokinetic strength and fatigability; Change from baseline in frailty status |
|
